✦ LIBER ✦

The dose-response relationship in Phase I clinical trials and beyond: use, meaning, and assessment

✍ Scribed by Gérard Emilien; Willem van Meurs; Jean-Marie Maloteaux

Book ID: 114129173
Publisher: Elsevier Science
Year: 2000
Tongue: English
Weight: 534 KB
Volume: 88
Category: Article
ISSN: 0163-7258
DOI: 10.1016/s0163-7258(00)00077-2

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Bayesian Dose-Finding in Phase I/II Clin

Bayesian Dose-Finding in Phase I/II Clinical Trials Using Toxicity and Efficacy Odds Ratios

✍ Guosheng Yin; Yisheng Li; Yuan Ji 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 339 KB

RE: Meta-analysis of the Relationship Be

RE: Meta-analysis of the Relationship Between Dose and Benefit in Phase I Targeted Agent Trials

✍ Jain, R. K.; Lee, J. J.; Hong, D.; Kurzrock, R. 📂 Article 📅 2013 🏛 Oxford University Press 🌐 English ⚖ 110 KB

Phase I clinical trial of fixed–dose rat

Phase I clinical trial of fixed–dose rate infusional gemcitabine and dacarbazine in the treatment of advanced soft tissue sarcoma, with assessment of gemcitabine triphosphate accumulation

✍ José M. Buesa; Raquel Losa; Aida Fernández; Marta Sierra; Emilio Esteban; Ángela 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 106 KB 👁 2 views

Estimating the safe starting dose in pha

Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose

✍ Joseph F. Contrera; Edwin J. Matthews; Naomi L. Kruhlak; R. Daniel Benz 📂 Article 📅 2004 🏛 Elsevier Science 🌐 English ⚖ 491 KB

A phase I trial assessing the safety, to

A phase I trial assessing the safety, tolerability, pharmacokinetic and pharmacodynamic characteristics of single-dose Auron Misheil therapy in healthy male subjects

✍ J. Scheele; K. Diergarten; J. Drevs; F. R. Niazi 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 217 KB

437 Biomarker Development for the Pharma

437 Biomarker Development for the Pharmacodynamic Assessment of CC-223, a Potent and Selective mTOR Kinase Inhibitor, in Phase I Clinical Trials

✍ Wong, L.; Liu, Y.; Wu, X.; Bauer, D.; Chen, B.; Hege, K.; Chopra, R.; Bendell, J 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 60 KB